These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 29204683)

  • 1. Wide difference in biologics usage and expenditure for the treatment of patients with rheumatoid arthritis in each prefecture in Japan analyzed using "National Database of Health Insurance Claims and Specific Health Checkups of Japan".
    Kamata Y; Minota S
    Rheumatol Int; 2018 Apr; 38(4):663-668. PubMed ID: 29204683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of introducing biologics to patients with rheumatoid arthritis in Taiwan: a population-based trend study.
    Lang HC; Lee HC; Lee SS; Lin HY; Chiu YM
    Int J Rheum Dis; 2016 Nov; 19(11):1112-1118. PubMed ID: 26890537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on the prevalence and incidence of rheumatoid arthritis in Korea and an analysis of medical care and drug utilization.
    Won S; Cho SK; Kim D; Han M; Lee J; Jang EJ; Sung YK; Bae SC
    Rheumatol Int; 2018 Apr; 38(4):649-656. PubMed ID: 29302803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes to the Australian Pharmaceutical Benefit Scheme restrictions for biological disease-modifying antirheumatic drugs have influenced the use of leflunomide.
    Hopkins AM; Vitry AI; O'Doherty CE; Proudman SM; Wiese MD
    Int J Rheum Dis; 2017 Nov; 20(11):1795-1797. PubMed ID: 26176865
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment Patterns, Direct Cost of Biologics, and Direct Medical Costs for Rheumatoid Arthritis Patients: A Real-world Analysis of Nationwide Japanese Claims Data.
    Sugiyama N; Kawahito Y; Fujii T; Atsumi T; Murata T; Morishima Y; Fukuma Y
    Clin Ther; 2016 Jun; 38(6):1359-1375.e1. PubMed ID: 27101816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost and effectiveness of biologics for rheumatoid arthritis in a commercially insured population.
    Curtis JR; Chastek B; Becker L; Quach C; Harrison DJ; Yun H; Joseph GJ; Collier DH
    J Manag Care Spec Pharm; 2015 Apr; 21(4):318-29. PubMed ID: 25803765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A European chart review study on early rheumatoid arthritis treatment patterns, clinical outcomes, and healthcare utilization.
    Emery P; Solem C; Majer I; Cappelleri JC; Tarallo M
    Rheumatol Int; 2015 Nov; 35(11):1837-49. PubMed ID: 26164150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimating effectiveness and cost of biologics for rheumatoid arthritis: application of a validated algorithm to commercial insurance claims.
    Curtis JR; Schabert VF; Harrison DJ; Yeaw J; Korn JR; Quach C; Yun H; Joseph GJ; Collier DH
    Clin Ther; 2014 Jul; 36(7):996-1004. PubMed ID: 25012729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Refining a Claims-based Algorithm to Estimate Biologic Medication Effectiveness and Cost per Effectively Treated Patient with Rheumatoid Arthritis.
    Popp RA; Rascati K; Davis M; Patel U
    Pharmacotherapy; 2018 Feb; 38(2):172-180. PubMed ID: 29197108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment patterns and annual biologic costs in US veterans with rheumatic conditions or psoriasis.
    Sauer BC; Teng CC; He T; Leng J; Lu CC; Walsh JA; Shah N; Harrison DJ; Tang DH; Cannon GW
    J Med Econ; 2016; 19(1):34-43. PubMed ID: 26337538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of Rheumatoid Arthritis and Drug Dispensing Patterns Among Medicaid and Medicaid-Medicare Dually Eligible Beneficiaries in Puerto Rico.
    Hernández-Muñoz JJ; Wei W; Sierra-Zorita R
    Arthritis Care Res (Hoboken); 2021 Feb; 73(2):199-206. PubMed ID: 32475025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inequalities in biologics utilization for rheumatoid arthritis according to socioeconomic status.
    Kwon OC; Park MC
    Korean J Intern Med; 2024 Jul; 39(4):545-546. PubMed ID: 38986494
    [No Abstract]   [Full Text] [Related]  

  • 13. Making smart investment decisions in clinical research.
    Bansback N; Keystone E; O'Dell J; Phibbs CS; Hannagan K; Brophy M; Anis A
    Trials; 2015 Dec; 16():590. PubMed ID: 26712327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient's access to healthcare and treatment in rheumatoid arthritis: the views of stakeholders in Portugal.
    Laires PA; Mesquita R; Veloso L; Martins AP; Cernadas R; Fonseca JE
    BMC Musculoskelet Disord; 2013 Sep; 14():279. PubMed ID: 24067096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and healthcare costs among stabilised rheumatoid arthritis patients with dose reduction of adalimumab or etanercept in real world.
    Yang M; Galebach PJ; Signorovitch JE; Garg V
    Clin Exp Rheumatol; 2017; 35(5):791-798. PubMed ID: 28339358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rheumatology practice in Japan: challenges and opportunities.
    Oku K; Atsumi T
    Rheumatol Int; 2019 Sep; 39(9):1499-1505. PubMed ID: 30888472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The spectrum of early rheumatoid arthritis practice across the globe: results from a multinational cross sectional survey.
    Nikiphorou E; Galloway J; van Riel P; Yazici Y; Haugeberg G; Ostor A; Gogus F; Kauppi M; Sokka T;
    Clin Exp Rheumatol; 2017; 35(3):477-483. PubMed ID: 28134086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost of biologic treatment persistence or switching in rheumatoid arthritis.
    Gu T; Mutebi A; Stolshek BS; Tan H
    Am J Manag Care; 2018 Jul; 24(8 Spec No.):SP338-SP345. PubMed ID: 30020745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perception of Originator Biologics and Biosimilars: A Survey Among Belgian Rheumatoid Arthritis Patients and Rheumatologists.
    van Overbeeke E; De Beleyr B; de Hoon J; Westhovens R; Huys I
    BioDrugs; 2017 Oct; 31(5):447-459. PubMed ID: 28929342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Which patients with rheumatoid arthritis, spondyloarthritis, or juvenile idiopathic arthritis receive TNF-α antagonists in France? The CORPUS cohort study.
    Saraux A; Benichou J; Guillevin L; Idbrik L; Job-Deslandre C; Sibilia J; Soudant M; Wendling D; Guillemin F
    Clin Exp Rheumatol; 2015; 33(5):602-10. PubMed ID: 26315585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.